- - Wednesday, October 12, 2016

Most would find incredible the notion that forcing up to 450 volts of electricity into a person’s brain to induce a grand mal seizure would not pose a high risk of catastrophic brain injury, yet the Food and Drug Administration (FDA) presumes, without the benefit of scientific proof, that the long-term effects of Electroconvulsive Therapy (ECT) pose no high risk for psychiatric patients.

Indeed, FDA has proposed that ECT be more readily available to patients with major depressive disorders. After decades of deeming shock therapy high risk Class III (requiring pre-market approval applications and full-blown clinical trials in proof of safety and efficacy), the FDA plans to deem it intermediate risk Class II (requiring only general and special controls from companies already marketing the devices). Instead of bowing to industry and expanding use of this barbaric “treatment,” FDA should ban ECT altogether.

After rejecting lobotomies in light of their horrific consequences, the FDA still clings to shock treatment, despite an equally long and tragic history. Refusing to demand proof of ECT safety and efficacy, the FDA has rejected its review panel’s recommendations to keep ECT in Class III, bending instead to industry by allowing marketing of the devices without pre-market approval, based solely on “special controls” that depend on listings of potential adverse effects in labeling and informed consent forms.

The supposed protection afforded by requiring informed consent from the mentally ill is no protection at all. In fact, many undergo shock treatment against their will following involuntary commitment, thus never having the option of informed consent. Many others have their judgment impaired by psychotropic drugs. Moreover, how can demand for informed consent mitigate the actual harms caused by ECT? FDA has no answers.

University of Pennsylvania professor of neuroscience Peter Sterling explained the damage caused by ECT in testimony before the New York State Assembly on July 18, 2001. He said, “Electroshock delivered to the skull is basically similar to what you … get out of an electrical wall outlet, except that there is a transformer in the ECT … that steps up the voltage.” Administered “two or three times a week for weeks,” ECT “causes … grand mal epileptic seizures,” an “acute rise in blood pressure, well into the hypertensive range” and “hemorrhages in the brain.” “[W]herever a hemorrhage occurs in the brain, nerve cells die, and they are not replaced.” “ECT … rupture[s] the blood brain barrier,” exposing “nerve cells in the brain to chemical insults that can kill them,” leading to “swelling of the brain,” which causes “local arrest of blood supply” and “loss of oxygen” and “death of neurons.” ECT “causes neurons to release large quantities of glutamate,” which “excites further neuronal activity” with neurons killing “themselves from over activity” and with injury manifesting itself in “retrograde memory loss.”

All patients who receive ECT suffer memory loss and cognitive impairment with many, if not most, experiencing severe memory loss, forgetting much of their lives before treatment (including who their children are, their spouse, and learned skills such as how to play the piano).

It is impossible to limit electrical flow when volts enter the brain. The risks are systemic, affecting vision, hearing, taste, olfactory function, the heart, all organs and all major muscle groups, resulting in physical disabilities, including death. The FDA reflects some of the risks in its “special controls,” admitting that ECT can cause “cardiovascular complications, death, and pulmonary complications.”

Although during the past three decades FDA repeatedly asked the industry to supply it proof of ECT safety and efficacy, the industry never did so, yet FDA never imposed a single penalty for noncompliance. In 2011, FDA’s Neurological Device Panel held a meeting on ECT reclassification and voted to keep the devices in Class III. Four years later, in December 2015, the FDA nevertheless proposed to reclassify ECT to Class II for some disorders.

To conclude that ECT no longer warrants high-risk designation, the FDA arbitrarily excluded from its record 94 percent of germane information. Many of the excluded studies concluded that ECT lacked efficacy and caused severe and permanent injury.

On Aug. 24, I filed a citizens’ petition to challenge the FDA’s intended reclassification. My office filed that petition on behalf of five patients who suffered severe, life-long ECT injuries. If the FDA bows to industry and reclassifies ECT from high to intermediate risk, we will sue the agency to prove the arbitrariness and capriciousness of its decision. We have asked the FDA to do what it should have done decades ago: ban these barbaric instruments, which bludgeon the brains and bodies of the mentally ill rather than treat them conscientiously.

Jonathan W. Emord is a constitutional and administrative law attorney, and a former vice president at the Cato Institute.

Copyright © 2023 The Washington Times, LLC. Click here for reprint permission.

Please read our comment policy before commenting.

Click to Read More and View Comments

Click to Hide